Editorial

Convalescent Plasma as a Last Resort

As of 3 April, the number of patients with coronavirus disease 2019 (COVID-19) in Korea has exceeded 10,000. The incidence of COVID-19 patients still shows no sign of diminishing. Now is the time to prepare for the protracted war ahead. Hence we need to find a specific treatment measure against COVID-19. Regrettably, however, no definite treatment has been available yet. Nevertheless, various treatments, including old and new antiviral agents, are currently being investigated.

As one of them, convalescent plasma administration has been carefully proposed. As one of them, convalescent plasma administration has been carefully proposed. In this issue, Ahn et al. have reported two cases of successful treatment of COVID-19 using convalescent plasma. At the same time as this report, five cases that were successfully treated in China have been published, too. And it is anticipated that more attempts will be made in the future.

In fact, the idea of using convalescent plasma for the treatment of viral diseases is not new. It has already begun to be tried in the early 20th century. It was a time when there was no effective antiviral agent, so it must have been devised with the feeling of catching a straw in danger of drowning. It’s better than not trying, but it seems to have achieved a little in the early days. Since then, convalescent plasma therapy has been attempted several times. Most recently, plasma therapy was applied to severe acute respiratory syndrome (SARS), influenza, Ebola virus, and Middle East respiratory syndrome coronavirus (MERS-CoV), and, albeit not always successful, it seems to have managed to get ‘not-bad’ results.

In this issue, Ahn et al. have reported two cases of successful treatment of COVID-19 using convalescent plasma. At the same time as this report, five cases that were successfully treated in China have been published, too. And it is anticipated that more attempts will be made in the future.

In fact, the idea of using convalescent plasma for the treatment of viral diseases is not new. It has already begun to be tried in the early 20th century. It was a time when there was no effective antiviral agent, so it must have been devised with the feeling of catching a straw in danger of drowning. It’s better than not trying, but it seems to have achieved a little in the early days. Since then, convalescent plasma therapy has been attempted several times. Most recently, plasma therapy was applied to severe acute respiratory syndrome (SARS), influenza, Ebola virus, and Middle East respiratory syndrome coronavirus (MERS-CoV), and, albeit not always successful, it seems to have managed to get ‘not-bad’ results.

You’ll Never Walk Alone

As the authors stated in this paper, there were several limitations in these treatment cases, although it was a happy ending. In one case, plasma was administered 3 weeks after the onset. Given viral kinetics, it was already time for the titer to start falling. It is also true that convalescent plasma treatment still lacks scientific evidence. In addition, proper
dosage and administration protocols have not been standardized yet. In both cases, plasma was administered when antiviral drugs and steroids were given. It is hard to tell that the successful treatment is not necessarily due to plasma, and it cannot be refuted even if it is interpreted as an effect of antiviral agent or steroid. Or it is possible that these three elements were combined to create a synergistic effect.

But I’m going to change the way of interpretation. Given the mechanism of convalescent plasma therapy, I think this combination is rather worth being recommended.

The targets of COVID-19 treatment should be largely divided into two categories. First, it is aimed at the virus itself. The first thing you can think of is destroying the body of the virus. However, destroying the virus itself is a concept of disinfection and is too dangerous for humans to apply. As a therapeutic agent, there are drugs that inhibit RNA-dependent RNA polymerase by inhibiting the replication of viruses (e.g., remdesivir), or drugs that inhibit protease (e.g., lopinavir/ritonavir).\(^1,11\) Another target is angiotensin converting enzyme 2 (ACE2), a gatekeeper and receptor for viruses to enter human cells. By raising the intracellular pH, glycosylation of ACE2 can be prevented to block the entry of the virus (e.g., chloroquine),\(^13,14\) or it can be prevented from binding to ACE2 in advance by sticking to the spike protein of the virus.\(^15,16\) The latter, not the former, is the antibody.

Considering the above treatment mechanisms, it can be seen that it is difficult to succeed with only one mechanism to treat COVID-19. Blocking a virus with antibodies is not enough to win the battle. We must also suppress the replication of the virus, and prepare for a cytokine storm that occurs during treatment.\(^17\) In conclusion, it makes no sense as to which of these treatment methods was a decisive factor in the successful treatment. Rather, it is necessary to combine all of these to engage in treatment.

**Does It Hurt?**

We need to examine another important problem in plasma treatment.

Is it safe?

Plasma therapy itself has important complications. Examples are transfusion-related acute lung injury (TRALI), circulatory overload, or anaphylaxis.\(^18\) Fortunately, no adverse events have been reported. Nevertheless, these complications should always be a concern.

There is also the possibility of side effects that have been raised recently. It is the antibody-dependent enhancement of entry (ADE). Neutralizing antibodies, once bound to the spike protein of the virus, cause a conformational change of the spike and, consequently, could trigger the paradoxical result of better entry into human cells through the IgFc receptor.\(^19-21\) This side effect has not yet been realized, but should be kept in mind in the future of plasma treatment and vaccine development.
We've Only Just Begun

Convalescent plasma therapy gives us a lot of hope, but there are challenges to overcome. In the implementation, thorough ethical verification is required, and donor selection criteria should be strictly enforced. And it needs further extensive research to see if it really works. To this end, I think that institutional support is required to approve every attempt as quickly as possible.

Again, it is time to focus all of our capabilities on treatment.

REFERENCES

1. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020;14(1):69-71. [PUBMED | CROSSREF]
2. Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liambruno GM, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus 2016;14(2):152-7. [PUBMED]
3. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020;20(4):398-400. [PUBMED | CROSSREF]
4. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Back YJ, et al. Use of convalescent plasma therapy in two COVID-19 patients with ARDS in Korea. J Korean Med Sci 2020;35(14):e149. [CROSSREF]
5. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. Forthcoming 2020. [PUBMED | CROSSREF]
6. Mair-Jenkins J, Saavedra-Cardenas M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015;211(1):80-90. [PUBMED | CROSSREF]
7. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005;24(1):44-6. [PUBMED | CROSSREF]
8. Yeh KM, Chiueh TS, Sui LC, Lin JC, Chan PK, Peng MY, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005;56(5):919-22. [PUBMED | CROSSREF]
9. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007;357(14):1450-1. [PUBMED | CROSSREF]
10. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011;52(4):447-56. [PUBMED | CROSSREF]
11. World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. https://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/. Updated 2014. Accessed April 5, 2020. [PUBMED | CROSSREF]
12. Kim JY, Ko JH, Kim Y, Kim YJ, Kim JM, Chung YS, et al. Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. J Korean Med Sci 2020;35(7):e86. [PUBMED | CROSSREF]
13. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30(3):269-71. [PUBMED | CROSSREF]
14. Vincent MJ, Bergeron E, Benjamini S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2(1):69. [PUBMED | CROSSREF]
15. Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol 2020;38(1):10-8.

16. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020;9(1):382-5.

17. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017;39(5):529-39.

18. Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion 2012;52(Suppl 1):65S-79S.

19. Wan Y, Shang J, Sun S, Tai W, Chen I, Geng Q, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol 2020;94(5):e02015-19.

20. Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcR pathway. J Virol 2011;85(20):10582-97.

21. Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun 2014;451(2):208-14.